The development of new combination therapy with deferasirox and sorafenib on advanced hepatocellular carcinama

点击翻译按钮获取中文摘要

Sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC). However, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering an oral iron chelator, deferasirox (DFX), on the effects of sorafenib. The combination of DFX+sorafenib markedly prevented liver fibrosis and preneoplastic lesions better than the other treatments. Furthermore, the combination therapy produced significantly fewer adverse effects such as body weight and hand-foot skin syndrome compared with the sorafenib group. The combination therapy with DFX and sorafenib may be a useful adjuvant therapy to prevent recurrence after curative treatment of HCC.